INTRODUCTION (Janis E. Hulla and Mark S. Miller)
Significant advancement in our understanding of the genetics underlying individual disease susceptibility has been achieved. Gene-linkage studies focused on familial disease clusters have identified distinct genes where inherited mutations predispose to disease. For example, mutations in p53, XPB, BRCA1, and ATM are predisposing to Li-Fraumeni syndrome, xeroderma pigmentosum, breast cancer and ataxia telangiectasia, respectively. Yet, diseases such as these, attributable to highly-penetrative, single-gene defects are relatively rare. Variations of susceptible genes, having relatively low penetrance, are likely to be of greater significance, since they are prevalent in the human population. In this regard, it is reasonable to predict that significant susceptibility will be found associated with genetic polymorphisms affecting cellular functions such as growth regulation, xenobiotic metabolism, and DNA repair. Indeed, polymorphisms of N-acetyltransferases, microsomal epoxide hydrolases, and paraoxonases are common in the general population, and definitions of the gene/environment linkage are progressing. As reported in this symposium review, evidence from animal and epidemiological studies links N-acetyltransferase genotypic and phenotypic polymorphisms with increased risk of colorectal cancer and predisposition to environmentally-induced bladder cancers. Functional variations among human microsomal epoxide hydrolases are established, and population-based studies aimed at defining the links to individual susceptibility are underway. Additionally, the incidence of two polymorphisms of the human serum paraoxonase gene have been identified, their functional significance in the metabolism of several organophosphates is established, and ongoing epidemiological studies are on the verge of discovering whether individual susceptibilities to organophosphate agents occur. Thus, important new information about the relationships between specific metabolic polymorphisms and disease susceptibilities has emerged.
Common DNA-replication and DNA-repair gene polymorphisms have not yet surfaced. Hence, the roles replication variations or repair variations have in environmental disease susceptibility are unknown. It is reasonable to speculate, however, that functional polymorphisms of replication and repair are enormously significant, since replication must proceed with high fidelity in a cellular environment where an estimated 10,000 nucleotides are damaged daily by normal chemical reactions. Beyond this level of damage, xenobiotic-induced alterations must be repaired with the same high fidelity. The discovery that mutations in mismatch repair genes underlie genomic instability found in a variety of human tumors supports the hypothesis that replication and repair polymorphisms contribute to environmental disease susceptibility. The leading edge in this regard is summarized as structure-function studies of mutant DNA polymerases and mutant mismatch repair genes.
GENE-ENVIRONMENT INTERACTION IN BLADDER CANCER RISK: A CASE-CONTROL STUDY (J. A. Taylor)
Bladder cancer is the fifth most common cancer in the United States, with over 52,000 new cases diagnosed per year. Environmental exposures, including to cigarette smoke and to substances typically used in certain occupations, are the principal known determinants of bladder-cancer risk. Genetic factors also play a role in determining an individual's risk of bladder cancer, particularly polymorphisms in the genes responsible for the metabolism of environmental carcinogens and perhaps those involved in DNA repair. We have completed a case-control study of bladder cancer (n ϭ 435), where both detailed-exposure and genotype information has been collected on a variety of polymorphic candidate susceptibility genes (Taylor et al., 1998) . We find evidence, not only for the main effects of exposure and genotype on risk, but also for geneenvironment and gene-gene-environment interactions that extends beyond additive or multiplicative models. Such findings suggest that the risks associated with an exposure, or with a particular genotype, may only be evident when both exposure and genotype are considered together (London et al. 1997; Packenham et al., 1995) . Although the relative risk of a specific genotype may be modest, it can still account for a surprisingly large attributable risk if the at-risk genotype is common.
ROLE OF N-ACETYLTRANSFERASE POLYMORPHISMS IN GENETIC PREDISPOSITION TO CANCER (David W. Hein)
Our understanding of genetic predisposition to cancer has expanded exponentially in recent years. With respect to cancers associated with chemical exposures, mechanistic hypotheses have focused on genetically determined variability in rates of metabolic activation and deactivation of the chemicals to their carcinogenic forms. Our laboratory, as well as many others, has focused on the role of the N-acetylation polymorphisms in genetic predisposition to cancer from aromatic and heterocyclic amine carcinogens.
A number of aromatic amines such as 4-aminobiphenyl, and heterocyclic amines such as 2-amino-1-methyl-6-phenylimidazo (4,5-b) pyridine (PhIP), are present in the environment from a number of sources, including cigarette smoke and foods. Four-aminobiphenyl is among a number of aromatic amines detected in nanogram quantities in mainstream cigarette smoke and in even higher levels in side-stream smoke (Patrianakos and Hoffman, 1979) . PhIP and other heterocyclic amines are also present in mainstream cigarette smoke (Manabe et al., 1991) and in the diet, particularly as protein pyrolysis products produced during the cooking of meat (Layton et al., 1995) .
Aromatic and heterocyclic amines require metabolic activation to ultimate carcinogenic forms. Following N-oxidation, the N-hydroxy-aromatic and -heterocyclic amines are further activated by O-acetylation to acetoxy-derivatives catalyzed by N-acetyltransferases (Hein, 1988) . Two distinct N-acetyltransferases exist in human and rodent populations, identified as NAT1 and NAT2 (Hein, 1988; Vatsis et al., 1995; Weber and Hein, 1985) . NAT2 is the "classical" acetylation polymorphism which segregates populations into rapid, intermediate, and slow acetylator phenotypes (Weber and Hein, 1985) , whereas NAT1 encodes a separate acetylation polymorphism (Vatsis et al., 1995) . Both NAT1 and NAT2 are capable of catalyzing the metabolic activation of aromatic and heterocyclic amine carcinogens Minchin et al., 1992) . Thus, genetic polymorphism in NAT1 and/or NAT2 could affect the metabolic activation of aromatic and heterocyclic amine carcinogens, which could affect cancer risk. Consistent with this hypothesis, investigations have shown associations between NAT2 acetylator phenotype and cancers of the breast, colon, lung, and urinary bladder. More recent studies have suggested associations between certain NAT1 alleles and cancers of the colon and urinary bladder (Bell et al., 1995a,b; Taylor et al., 1995) .
Human epidemiological studies investigating the role of N-acetyltransferase polymorphisms in colorectal cancer illustrate the complexity inherent in these studies. Heterocyclic amine carcinogens such as PhIP are efficacious colon carcinogens in rodents (Ito et al., 1991) , and humans are exposed to them primarily as a dietary carcinogen (Layton et al., 1995a,b) . The prevailing mechanistic hypothesis suggests that rapid acetylators should more readily activate heterocyclic amine carcinogens present in the diet to their ultimate carcinogenic forms, and therefore have enhanced risk of colorectal cancer, assuming no other differences in carcinogen metabolism or exposure. Since human populations are genetically heterogeneous and exposures are difficult to estimate, much less match, it is not surprising that consistent results have not been forthcoming. Thus, although several investigations (Gil et al., 1998; Ilett et al., 1987; Lang et al., 1986; Roberts-Thompson et al., 1996) have shown an association between rapid NAT2 FORUM acetylator phenotype and colorectal cancer, a larger number of studies Hubbard et al., 1997; Ladero et al. 1991; Probst-Hensch et al., 1995; Rodriguez et al., 1993; Shibuta et al., 1994; Spurr et al., 1995; Welfare et al., 1997) have failed to show this association. One study is unique among all of the studies above, in that it also investigated a possible role for the human NAT1 polymorphism. Their study found an association between the NAT1*10 allele and colorectal cancer, and the risk is most apparent among NAT2 rapid acetylators, suggesting a gene-gene interaction between NAT1 and NAT2.
Recent discoveries of additional NAT1 and NAT2 alleles suggest that further studies are needed. As of this date (February 1998), our laboratory is aware of 19 different NAT1, and 24 different NAT2 alleles have been identified in human populations. Because many of these alleles were not known at the time of the epidemiological investigations listed above, comprehensive analysis for associations between NAT1 and NAT2 allelic frequencies in colorectal, or any other, cancer has not yet been published. Our laboratory (Hein et al., ,b, 1995 and others (Butcher et al., 1998; Delomenie et al., 1997; Doll et al., 1997; Grant et al., 1992; Hein et al., 1998; Hickman et al., 1995; Lin et al., 1998) have investigated the role of NAT1 and NAT2 nucleotide substitutions on acetyltransferase catalytic activities using recombinant expression systems. These studies suggest that the various nucleotide substitutions identified in human NAT1 and NAT2 17 clusters have differing reductions in catalytic activity, while recombinant human NAT2 12 and NAT2 13 clusters catalyze acetyltransferase activities at levels comparable to the prototypic "rapid" acetylator allele NAT2 4 (Hein et al., 1994a,b; . Furthermore, the recombinant NAT2 also encode proteins that differ in intrinsic stability, as the NAT2 7, NAT2 14 and NAT2 18 clusters are markedly less stable than the others. With respect to human NAT1, several of the alleles, most notably NAT1*14, which encodes a single amino acid change (Arg 187-Gln) that decreases substrate affinity and NAT1*15, which encodes a premature stop codon (Arg 188-stop), are considered slow NAT1 acetylator alleles (Hughes et al., 1998) . Some studies suggest that NAT1*10 may be a rapid acetylator allele, since it has been associated with elevated NAT1 activity in bladder and colon tissues and increased carcinogen-DNA adduct binding in the urinary bladder (Badawi et al., 1995) . A rapid NAT1 allele has yet to be confirmed using recombinant expression systems. Furthermore, none of the epidemiological studies to date have discriminated between all the possible NAT1 and NAT2 alleles, as many of them have been identified only very recently and others may yet be identified. Thus, certain combinations of NAT1 and NAT2 alleles, heretofore not identified, may yield the highest susceptibility toward aromatic or heterocyclic amine-related cancers. Further molecular epidemiological studies of this nature are in progress in our laboratory and others to investigate this hypothesis.
In addition to humans, NAT2 acetylation polymorphism in several rodent models is also well-characterized . Our laboratory has investigated the role of the NAT2 acetylator polymorphism in colorectal cancer using rapid and slow acetylator congenic hamster and rat models. The molecular basis for the acetylation polymorphism in the congenic hamster and rat is summarized in Table 1 . The slow acetylator hamster is homozygous for the NAT2*16A allele, which contains a C727T nucleotide mutation that yields a premature stop codon (Arg 243-stop) and a truncated NAT2 protein with substantially reduced catalytic activity (Ferguson et al., 1994a,b; . The slow acetylator inbred rat is homozygous for the NAT2*21A allele that contains four nucleotide substitutions, two of which are silent on amino acid level, and two of which are missense substitutions that reduce catalytic activity Hein et al., 1997) . We tested the hypothesis that rapid NAT2 acetylator genotype would predispose to colorectal cancer in rapid and slow acetylator congenic hamster and inbred rat models administered aromatic amine carcinogens. We measured the frequency of aberrant crypts, which are the earliest morphologically evident preneoplastic lesions of colon cancer in humans and rodents (Pretlow et al., (Feng et al., 1996) .
b Rapid acetylator significantly higher than slow in Bio.1.5/H-NAT2 cogenic line (Paulsen et al., 1996) .
c Rapid acetylator significantly higher than slow 1991). As shown in Table 2 , we clearly observed a higher frequency of aberrant crypt foci in rapid versus slow acetylators in two different congenic hamster models and in the inbred rat model. These studies clearly support the role of the NAT2 acetylation polymorphism in colorectal cancer that was evident in some of the human epidemiological studies. Further studies using these models are needed to test associations between N-acetyltransferase polymorphisms and cancers at other organ sites.
THE PON1 POLYMORPHISM (Clement E. Furlong)
A growing body of evidence suggests that genetic variability plays a major role in determining individual sensitivity or resistance to different environmental exposures. The human serum paraoxonase (PON1) polymorphism has been cited as one clear example of the role of genetic variability in environmental disease (Kaiser, 1997) .
Human serum paraoxonase (PON1) is a high-density, lipoprotein particle-associated enzyme that exhibits a substratedependent polymorphism in human populations (reviewed in Geldmacher-von Mallickrodt and Diepgen, 1988) . Its role in the metabolism of organophosphate compounds (OP) has been studied for much longer than its role in lipid metabolism. Early studies with this enzyme indicated that there appeared to be two isoforms, one that rapidly hydrolyzed paraoxon, the toxic oxon metabolite of the parent insecticide parathion, and one isoform that hydrolyzed this oxon slowly. Over the years, many different enzyme assays were developed for use in characterizing this polymorphism in human populations (OrtigozaFerado et al., 1984) . Finally, in 1991, we succeeded in cloning and characterizing the human and rabbit PON1 cDNAs (Hassett et al., 1991) . Further work led to the elucidation of the molecular basis of the polymorphism in human populations (Humbert et al., 1993) . A Gln/Arg substitution at position 192 of PON1 changes the rates of hydrolysis of a number of OP substrates hydrolyzed by PON1. The Arg 192 isoform (PON1R192) hydrolyzes paraoxon rapidly, while the Gln 192 isoform (PON1Q192) hydrolyzes paraoxon slowly. Following these observations, PON1R192 was thought of as "the high activity PON1" isoform and PON1Q192 as the "low activity" PON1 isoform. Recently, however, we demonstrated that the effect of this polymorphism was reversed for other OP compounds (Davies et al., 1996) . PON1Q192 hydrolyzed diazoxon, soman, and especially sarin faster than PON1R192. Thus, it became apparent that the effect of the polymorphism was substrate dependent.
As noted above, most of the early research on PON1 was related to the metabolism of xenobiotics. Only recently, was it demonstrated that PON1 plays a role in the metabolism of oxidized lipids (Watson et al., 1995) . Although we will not discuss the effect of the PON1 polymorphism on lipid metabolism, it is important to remember that what is said about the effect of genetic variability of OP metabolism probably is valid for understanding genetic variability of lipid oxidation and vascular disease.
La Du and co-workers pioneered the use of two-dimensional enzyme analysis for characterizing the PON1 polymorphism in human populations (Eckerson et al., 1983) . This approach has proven to be very useful in understanding the genetic variability of PON1 in human populations. Figure 1 (Davies et al., 1996, with permission) shows the application of this approach to investigating the population frequency distributions for the hydrolysis of 5 different PON1 substrates in a population of Hispanic farm workers. It is clear that the plot of the rates of hydrolysis of diazoxonase vs. paraoxonase clearly resolves the population into three groups, individuals homozygous for the Gln192 isoform (E), heterozygotes (s) and individuals homozygous for the Arg 192 isoform (‚). The most important point to note about the distributions is that, for each genotype, there is a large variation in the level of enzyme expressed that is stable over time. At this point, we would like to introduce a definition for the PON1 polymorphism. It is PON1 status, which includes both phenotype and genotype, or the point at which an individual falls within a population distribution. From such a treatment of data, it is also easy to calculate the gene frequency for the Gln/Arg alleles. It should be noted, however, that it does not provide information on the position 55 Leu/Met polymorphism in the Q192 homozygotes or heterozygotes. (All of the Arg 192 alleles appear to encode Leu at position 55). It is also clear from this plot that the effect of the polymorphism is reversed for diazoxon hydrolysis. Individuals homozygous for the Arg 192 isoform hydrolyze diazoxon more slowly than individuals homozygous for the Gln 192 isoform.
Examination of the other two-dimensional enzyme plots show that the effect of the polymorphism is also reversed for soman hydrolysis and especially for sarin hydrolysis, where the Arg 192 allele is virtually a null allele.
This type of plot, as well as PCR assays, has been used to generate gene frequencies for the PON1 alleles in different populations. The plots here demonstrate that the gene frequency for the Arg 192 allele was 0.41 in the studied population of Hispanic farm workers (Davies et al., 1996) . Gene frequencies for northern European populations have been reported by a number of groups to be about 0.3. Recent data indicate that the gene frequency in Japanese for the Arg 192 allele is 0.66 (Yamasaki et al., 1997) , suggesting that this population would have a high percentage of individuals who are especially sensitive to sarin.
Some correlative data exist on the relationship between serum hydrolytic levels of OP's by PON1 and resistance to specific OP compounds (Furlong et al., 1989) . We decided to directly test the hypothesis that high PON1 levels were protective against OP toxicity. We injected purified rabbit PON1 into mice and demonstrated that rabbit PON1 protected against toxicity of chlorpyrifos oxon as well as exposure to the parent compound chlorpyrifos. The PON1 protected if it was injected pre or shortly after exposure (30 min). Some protection was observed with injection as late as 3-h post exposure (Li et al., 1995) .
What about low PON1 levels? Our recent studies have demonstrated that PON1 knockout mice are exceptionally sensitive to chlorpyrifos oxon and chlorpyrifos. Sensitivity to the oxon metabolites is significant, since not only are they generated in vivo by the cytochrome P450 systems, but they may also be present at high levels in foliar residues. Although very little epidemiological data exist regarding enzyme levels and resistance or sensitivity to Op's, we found that a cohort of 90 pesticide applicators, who sprayed mostly chlorpyrifos, had virtually no low metabolizers. There is a need for high quality epidemiological data for human populations.
The existing data from enzyme injection experiments provide a strong case that high levels of PON1 are protective against OP compounds processed through the P450/PON1 pathway, at least for the case of chlorpyrifos. The data generated with the PON1 knockout mice clearly show them to be very sensitive to chlorpyrifos and its oxon metabolite. What about our earlier observation of very low PON1 levels in newborns (Mueller et al., 1983) ? These data suggest that it is prudent to avoid exposing newborns to PO insecticides. WanFen Li has examined the time course of PON1 development in rats and mice and has found that it takes approximately 3 weeks for PON1 in the serum to reach adult levels . Earlier studies in the literature indicate that PON1 levels in human newborns have not reached adult levels by 6 months of age (Augustinsson and Barr, 1963) .
We feel that it is important to continue the development of the mouse model for use in generating predictive PBPk models. Expressing each human PON1 isoform in the knockout mouse background should allow for the generation of populations of mice that mimic the genetic variability observed in human populations.
The take-home message for evaluating human PON1 genetic variability is that PON1 status, determined by a high throughput, two-dimensional enzyme assay, is much more important than genotype alone. The position-55 polymorphism is still best evaluated by PCR assay; however, it does not appear to affect the rates of substrate hydrolysis like the position-192 polymorphism.
GENETIC POLYMORPHISM OF HUMAN MICROSOMAL EPOXIDE HYDROLASE (C. J. Omiecinski)
Frequently, the metabolism of foreign substances, including environmental chemicals and pharmaceuticals, results in detoxification. However, the metabolism process also may lead to the generation of bioactivated and toxic intermediates. In particular, epoxide metabolites may be formed through oxidation by cytochrome P450 enzymes, generating chemically reactive and cytotoxic products (Sayer et al., 1985; Adams et al., 1995; Guengerich, 1982; Thakker et al., 1986) . The family of epoxide hydrolases function to hydrate simple epoxides to vicinal diols and arene oxides to trans-dihydrodiols. These enzymes are but one category of a broader group of hydrolytic enzymes that include esterases, proteases, dehalogenases, and lipases FIG 1. Application of two-dimensional enzyme analysis to investigating the population frequency distributions for the hydrolysis of 5 different PON1 substrates in a population of Hispanic farm workers. It is clear that the plot of the rates of hydrolysis of diazoxonase vs. paraoxonase clearly resolves the population into three groups, individuals homozygous for the Gln192 isoform (E), heterozygotes (s) and individuals homozygous for the Arg 192 isoform (‚). Reproduced from Davies et al. (1996) with permission. (Beetham et al., 1995) . The microsomal form of epoxide hydrolase (mEH) has been demonstrated to possess hydrolytic activity for a broad range of xenobiotic epoxides. Although this metabolism typically results in less reactive and therefore detoxified products, bioactivated and highly reactive intermediates can also be generated, e.g., in the metabolism of polyaromatic hydrocarbons to bay region diol-epoxides (Sayer et al., 1985 , Wood et al., 1986 . In addition to substrates generated through oxidative pathways in situ, direct exposure to epoxides can also occur, as with styrene oxide (Rappaport et al., 1996) .
The structural characterization of the human gene and cDNA mEH has led to the identification of genetic polymorphism at this locus (Gaedigk et al., 1994; . Two principal functional genetic polymorphisms have been delineated in the gene's coding region, one resulting in either a His or a Tyr substitution at an amino acid position (Gaedigk et al., 1994; . When the corresponding cDNAs were expressed in vitro, the resulting activities ranged approximately 2-fold, with the Tyr113/Arg139 construct exhibiting the highest overall activity and the His113/His139 exhibiting the lowest . Despite this variation, specific activities measured for the expressed proteins did not appear to differ ; rather, the available data indicate that altered protein stability may account for the altered levels of expression . Evidence supporting the role of post-transcriptional regulatory control of microsomal EH expression has been advanced in several studies Hassett et al., 1997; Omiecinski et al., 1994) . It is noteworthy that, in addition to the coding region polymorphism, the mEH gene is polymorphic within its 5'-flanking region as well, with seven non-coding polymorphisms having been identified (Raaka et al., 1998) .
Studies aimed at exploring the potential contribution of altered mEH genotype to altered susceptibility to disease incidence are only beginning. In this regard, results from several molecular epidemiological investigations have been reported recently. McGlynn et al. (1995) conducted a molecular epidemiological investigation to examine hepatocellular carcinoma incidence in a Chinese population. They reported that individuals with at least one lower activity His113 allele exhibited a 3.3-fold increased risk of developing hepatocellular carcinoma, even when considered independent of glutathione transferase M1 genotype or hepatitis B virus exposure. However, individuals with both viral infection and the high-risk EH genotype exhibited Ͼ77 times the risk of disease compared to individuals with neither predisposing factor (McGlynn et al., 1995) . In contrast, a study by Lancaster et al. (1996) concluded that an increased risk for ovarian cancer was associated with the higher activity Tyr113 EH allele, with an associated-odds ratio of 2.6. Another investigative team examined bladder-cancer relative risk and concluded that microsomal EH allelic status was not associated with disease incidence (Brockmoller et al., 1996) . A relatively recent report in Lancet concluded that individuals homozygous for microsomal EH His113 exhibited increased likelihood of pulmonary disorders with odds ratios of 4.1 (95% CI 1.8 -9.7) for chronic obstructive pulmonary disease and 5.0 (95% CI 2.3-10.9) for emphysema .
A recent study from our laboratory was focused on examining the range of mEH functional expression in humans. We characterized the relationships between mEH enzymatic activity, protein level, mRNA content, and corresponding genotype, using a panel of 40 transplant-quality human liver samples (Hassett et al., 1997) . Approximately an 8-fold variation was noted for the range of mEH hepatic enzyme activity and corresponding mEH protein content in these human samples. These respective measures of functional expression were highly correlated with one another but rather poorly correlated with mEH RNA content. However, the mEH polymorphic amino-acids genetic analyses performed on these tissues did not exclusively predict mEH phenotype (Hassett et al. 1997) .
Induction of specific biotransformation enzymatic activities can potentially alter the disposition and toxicologic fate of substances to which we are exposed. Experiments with animal models have demonstrated that xenobiotic exposures often modulate basal expression patterns of xenobiotic-metabolizing genes. Since species differences exist in biotransformation enzyme profiles, predicting genetic effects of chemical exposures in humans from data obtained with animal experiments can be difficult. We have used cultures of primary human hepatocytes to examine the responsiveness of the mEH gene to an array of prototypic chemical inducing agents . Results from these studies indicated that, despite the high degree of responsiveness of cytochrome P450 marker genes to chemical treatment in these cultures, human mEH expression was only modestly affected by these agents .
The mEH enzyme system is an important determinant of epoxide disposition. Further studies will be required to more thoroughly explore the molecular pathways regulating mEH genetic expression in human cells and tissues. Similarly, additional investigations examining potential relationships between EH allelic status and risk of disease development will be required to definitely evaluate potential associations, with an emphasis toward large, well-controlled epidemiological investigations and combined analyses with other potential risk determinants.
DNA REPLICATION FIDELITY, MISMATCH REPAIR, AND GENOME INSTABILITY (T. A. Kunkel)
Cells accurately replicate their genomes using three major processes for discriminating against errors. DNA polymerases accurately select correct dNTPs for incorporation, and occasional mistakes are edited by proofreading exonucleases. Rare errors left behind by the replication machinery are corrected by DNA mismatch repair. We are examining the contribution of each of these processes to genome stability in human cells. To understand the interactions between a DNA polymerase and its substrates, which are critical for controlling replication fidelity, we are performing structure-function studies of mutant DNA polymerases containing single amino acid differences, introduced based on crystal structure information. We have obtained several derivatives of Klenow polymerase, HIV-1 reverse transcriptase and DNA polymerase beta that have elevated rates for substitution and frameshift errors. Analyses of these enzymes are revealing interactions of residues in the "fingers", "palm" and "thumb" subdomains of polymerases with either the active-site template base or the duplex templateprimer stem that determine the rates for errors initiated either by direct miscoding or by template-primer slippage, respectively. We are also examining the role of mismatch-repair in correcting replication errors. We have identified a panel of human tumor-cell lines from a variety of tissue types that are defective in mismatch repair, are resistant to treatment with MNNG, and have elevated mutation rates in microsatellite sequences. These cells contain mutations in the mismatchrepair genes hMSH2, hMSH3, hMSH6, hMLH1, and hPMS2. The mismatch-repair defects, MNNG resistance, and microsatellite instability in lines containing defects in these genes have been corrected by introducing the relevant wild-type human chromosome. These lines are being used to examine the biochemical and biological functions of mismatch repair in human cells and of the connection between the defects in these functions, tumorigenesis, and resistance to chemotherapeutic agents (Beard et al., 1996; Bebenek et al., 1997; Bell et al., 1997; Hermann et al., 1998; Kunkel et al., 1998; Minnick et al., 1996; Risinger et al., 1996; Umar et al., 1996 Umar et al., , 1997 Umar et al., , 1998 Winter et al. 1998) .
